A British nanotech company has created a potentially life changing technology that aims to overcome the global crisis of antibiotic resistance.
Researchers from AGA Nanotech ltd, working with University College London (UCL), have developed a unique alternative to antibiotics.
They have enabled the safe and effective delivery of antimicrobials which do not give rise to resistance. Borrowing approaches used in oncology, they have identified a means of delivering high energy oxidative molecules to the site of infection without harming the patient.
By loading particles produced by a Thermally Induced Phase Separation (TIPS) technique developed by Dr Richard Day at UCL, they have been able to use microparticles to direct the controlled delivery of antimicrobial agents straight to the site of infection.
The use of nanoplatforms allows the delivery of highly oxidative biocides directly to infecting bacteria without being toxic to the body. Unlike antibiotics, its unique properties allow it to overcome any antibiotic resistance the bacteria may have.
According to the World Health Organisation (WHO), antibiotic resistance is one of the biggest threats to global health. It can affect anyone, of any age, in any country.
It has also led to infections such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases, becoming difficult and in sometimes impossible to treat as antibiotics become less effective.
The AGA Nanotech precursor loaded TIPS particles provide an innovative antimicrobial alternative to classic antibiotic agents and could serve as adjunctive or replacement therapy.
The first application from the company will be in the field of wound care, however the technology can be adapted for pulmonary, oral or systemic delivery. It offers great potential for the creation of bespoke approaches to different clinical conditions and also avoids the issue of continually bringing new expensive antibiotics to market.
AGA Nanotech was set up with the ultimate aim of overcoming the increasing problem of antibiotic resistance.
Their current technology incorporates precursors for hydrogen peroxide and peracetic acid within nanoparticles and microparticles. This approach is preferred because the inert precursors deliver highly reactive oxidative biocides, and hence do not give rise to resistance, but have low systemic toxicity and breakdown to give benign residues.
Adrian Fellows of AGA Nanotech said: “We can engineer biodegradable nanoparticles that have a broad range of physical and biological properties that can specifically target an organ or infection site, this is both novel and transformative.
“Our research demonstrates that we can load precursor compounds, release them in a controlled way and convert them into oxidative species.”
More information about AGA Nanotech
AGA Nanotech ltd is a UK R&D company part owned by Gama Healthcare Ltd. AGA Nanotech’s overall mission is to overcome the increasing problem of antibiotic resistance. To date the company have successfully incorporated a range of precursors types of PLGA nanoparticles. For one of these routes controlled release has been demonstrated.
In vitro tests against clinical isolates of MDROs at UCLH were successful, as were cytotox and subcutaneous safety studies. Further collaboration is underway to evaluate the technology against deeper seated infections. A licence agreement has been signed between UCLB and AGA Nanotech. Initial patents have been granted.